Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20732042 | 1.00 | CA1 (0.54) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL30061512 | 0.88 | CA1 (0.54) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL20732046 | 0.88 | CA1 (0.54) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL13234277 | 0.86 | CA1 (0.52) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL20840969 | 0.85 | CA1 (0.54) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL29630894 | 0.84 | CA1 (0.51) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL13213509 | 0.84 | CA1 (0.51) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL24479503 | 0.82 | CA1 (0.52) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL20722797 | 0.81 | CA1 (0.48) | CA1CA2ACHETSHRALDH1A1 | |
| SCHEMBL13213517 | 0.80 | CA1 (0.55) | CA1CA2ACHETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116490506-B | Fused tricyclic compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240360133-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4253387-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116490506-A | Fused tricyclic compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022111636-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CA1 1259/4885CA2 2429/4885ACHE 1811/4885 |
| US-20240360133-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | TLR7, TLR8, TLR9 | CA1 3529/4885CA2 3350/4885ACHE 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.